Triple drug therapy for advanced heart failure with preserved ejection fraction
Part of Heart & circulation clinical trials.
This trial tests a combination of three heart failure drugs (ARNI, SGLT2i, MRA) to see if they improve symptoms and outcomes in people with a type of heart failure where the heart pumps normally but doesn't relax properly (HFpEF).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have heart failure symptoms like shortness of breath or swelling.
- Your heart's squeezing ability is normal (ejection fraction over 50%).
- Your NT-proBNP levels are above a certain threshold (higher if you have atrial fibrillation).
- You have specific signs of heart muscle stiffness or relaxation problems on an echocardiogram.
- You have not taken ARNI, SGLT2i, or MRA drugs for more than 90 days straight in the past year, and have been off them for at least 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a combination medication (sacubitril/valsartan) can improve the heart's ability to relax and fill properly in people with heart failure and a very weak heart pump (ejection fraction less than 35%). It's for patients who are already on standard heart failure medicines.
This trial studies whether a heart medicine called ARNI (sacubitril-valsartan) is safe and works well for people who have a durable LVAD and moderate-to-severe heart pumping weakness. It may help improve symptoms and outcomes, while carefully checking side effects in this higher-risk group.
This trial tests whether combining exercise with a medication that blocks a protein called activin can reduce inflammation, improve heart function, and help with thinking in people with heart failure with preserved ejection fraction (HFpEF).
This trial tests an investigational drug for people with a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug can improve symptoms and quality of life.
This trial tests a procedure called pulmonary artery denervation for people with heart failure who still have a normal pumping ability. It aims to improve symptoms like shortness of breath and reduce fluid buildup.
This trial tests a new, faster way to increase heart failure medications during a hospital stay, aiming to get patients on the right doses sooner. It is for people with weak heart pumping (ejection fraction 40% or less) who are currently in the hospital for heart failure and are on low doses of standard medications.
Hear when a new HFpEF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.